Ginkgo Bioworks Unveils AI Data Generation Service, Boosting Stock and Analyst Optimism

Ginkgo Bioworks unveils new AI data generation service By Investing.com

BOSTON - Ginkgo Bioworks (NYSE: DNA), a company focused on cell programming and biosecurity, has announced the introduction of Ginkgo Datapoints, a new service designed to facilitate the training of artificial intelligence (AI) models in the field of biotechnology. The service will provide large-scale, high-quality biological datasets, with the first products available this fall, including offerings in protein characterization and functional genomics. The flagship product, Functional Genomics, currently available, aims to support AI models used in target identification, validation, and drug discovery. Ginkgo Datapoints seeks to address industry challenges related to data availability, quality, and uniformity, which are critical for the training of AI models in life sciences. According to Jason Kelly, CEO of Ginkgo Bioworks, Ginkgo Datapoints represents a significant advancement in the company's mission to simplify biological engineering. By offering large datasets at a competitive price, the service is expected to accelerate innovation and the development of new therapies within the biotech industry. John Androsavich, General Manager of Ginkgo Datapoints, highlighted the growing demand for data by drug and product developers who are increasingly relying on AI. The service is designed to be flexible and customizable, allowing customers to provide their own sequences or library inputs and select from various dataset parameters. Ginkgo Datapoints leverages Ginkgo's automated lab infrastructure to deliver data points efficiently, with the potential to provide millions of data points within a three-week timeframe. The service also offers volume discounts and attractive deal terms, with customers retaining ownership of the data generated. This initiative is an evolution of Ginkgo's previous Lab Data-as-a-Service offerings and underscores the company's commitment to enabling the full potential of AI in biology. While the press release contains forward-looking statements regarding the service's capabilities, it also acknowledges the competitive and regulated nature of the industry, as well as the risks and uncertainties that could impact the success of Ginkgo Datapoints. The information for this article is based on a press release statement from Ginkgo Bioworks. In other recent news, Ginkgo Bioworks has been at the center of several significant developments. The company retained its Buy rating and $3.00 price target from TD Cowen, reflecting its growth in the AI sector, particularly in AI-driven drug discovery. This was further bolstered by the expansion of its partnership with Google (NASDAQ:GOOGL) Cloud and the introduction of an open API. However, the New York Stock Exchange (NYSE) has delisted Ginkgo Bioworks' public warrants due to low trading price levels, though this does not affect the company's Class A common stock. Ginkgo Bioworks has also regained compliance with NYSE's listing standards after a period of non-compliance and the implementation of a 1-for-40 reverse stock split. Despite a 20% decrease in cell engineering revenue to $36 million, the company continues to expect cell engineering revenue between $120 million to $140 million for the full year. BTIG and Goldman Sachs (NYSE:GS) have adjusted their price targets for Ginkgo Bioworks to $7.00, maintaining a Sell rating. These are recent developments that investors should take into consideration. As Ginkgo Bioworks (NYSE: DNA) launches its Ginkgo Datapoints service to enhance AI model training in biotechnology, investors and industry watchers are closely monitoring the company's financial health and market performance. According to InvestingPro data, Ginkgo Bioworks holds a market capitalization of $379.38 million. Despite the innovative strides in services like Ginkgo Datapoints, the company's revenue has seen a decline of 43.45% over the last twelve months as of Q2 2024, with a gross profit margin remaining strong at 80.22%. This indicates that while Ginkgo is able to maintain high margins on its products and services, it is facing challenges in growing its top-line revenue. The stock price has experienced significant volatility, with a notable return of 9.13% over the last week, yet a steep decline of 59.56% over the last three months. This suggests that while there may be short-term gains, investors have concerns about the company's longer-term performance. One of the InvestingPro Tips highlights that Ginkgo Bioworks is trading at a low revenue valuation multiple, which could be a point of interest for value investors seeking companies with potential upside. Additionally, the company holds more cash than debt on its balance sheet, providing some financial stability amidst the cash burn concerns. While Ginkgo Bioworks does not pay a dividend to shareholders, which may be a drawback for income-focused investors, it's worth noting that the company's liquid assets exceed its short-term obligations, indicating a degree of liquidity that could support its operations and investment in initiatives like Ginkgo Datapoints. For those interested in a deeper dive into the company's prospects, InvestingPro offers a total of 16 additional tips available at https://www.investing.com/pro/DNA, which can provide further guidance on Ginkgo Bioworks' valuation and performance metrics.

What's Going On With Ginkgo Bioworks Stock This Week? - Ginkgo Bioworks Holdings (NYSE:DNA)

Ginkgo Bioworks announces the launch of Ginkgo Datapoints, which aims to make the training of AI models easier and more efficient. Ginkgo Bioworks Holdings Inc DNA shares continue to trade higher after rising nearly 10% on Tuesday. Here's a look at what's going on. What To Know: Ginkgo Bioworks shares appear to be getting a boost Wednesday morning after the company announced the launch of Ginkgo Datapoints, which aims to make the training of AI models easier and more efficient. Ginkgo said its Datapoints product can generate large biological datasets quickly at a competitive price per datapoint with a streamlined deal structure. Ginkgo Datapoints is expected to launch with several data generation products in the fall. "The launch of Ginkgo Datapoints marks a significant step forward in our mission to make biology easier to engineer," said Jason Kelly, CEO of Ginkgo Bioworks. "With Ginkgo Datapoints, we're passing on our economies of scale to our customers by generating large, high-quality datasets for our customers at a price per dataset that makes training biological foundation models feasible." The news comes just a day after Ginkgo shares rallied close to 10% after the company announced the launch of its new protein large language model built on Google Cloud. The company's protein LLM, built in collaboration with Google Cloud Consulting, will allow individual researchers and enterprise companies to develop medicines with insights from Ginkgo's private data. Ginkgo Bioworks also announced the launch of its model API, designed to deliver biological AI models directly to machine learning scientists. The company's new API became publicly available on its website on Tuesday. Ginkgo said it plans to roll out more models and expand API capabilities over the next year. Check This Out: Is The Fed Playing With Fire? 'We See Greater Risk Of An Overheating Economy' As They Cut Rates, Veteran Investor Warns DNA Price Action: Ginkgo Bioworks shares closed Tuesday up 9.31%. The stock was up 1.26% Wednesday morning, trading at $6.89 at the time of publication, according to Benzinga Pro. Photo: LaCasadeGoethe from Pixabay. Market News and Data brought to you by Benzinga APIs

Ginkgo Bioworks Stock Is Rallying Tuesday: Here's Why - Ginkgo Bioworks Holdings (NYSE:DNA)

Ginkgo Bioworks announces the launch of a model API, designed to deliver biological AI models directly to machine learning scientists. Ginkgo Bioworks Holdings Inc DNA shares are surging Tuesday after the company announced the launch of its new protein large language model (LLM) built on Google Cloud. What Happened: Ginkgo Bioworks has introduced a pair of new offerings aimed at making it easier for pharmaceutical and biotech companies to develop new medicines. The company's protein large language model, built in collaboration with Alphabet Inc's GOOG Google Cloud Consulting, will give individual researchers and enterprise companies the ability to develop medicines with insights from Ginkgo's private data. "Ginkgo's new protein LLM and open API mark a major step forward in making advanced AI tools accessible for drug discovery and biological research," said Chris Sakalosky, vice president of strategic industries at Google Cloud. Ginkgo Bioworks also announced the launch of its model API, designed to deliver biological AI models directly to machine learning scientists. The company noted that the new API is publicly available on its website as of Tuesday. Check This Out: Retail Sales Rise 0.1% In August, More Than Expected, Boosting Odds Of Larger Fed Rate Cut "I'm excited to see how the community builds on top of these models and our API. AA-0 is the first model we have released trained on Ginkgo's proprietary data - we're opening it to data scientists and bioinformaticians so they can build new models and applications on top," said Jason Kelly, CEO of Ginkgo Bioworks. "We believe that the low cost for tokens and our other customer-friendly terms, like the lack of royalties, and our commitment to not re-use customer data, will allow users to build tools like iterative protein design programs that call our protein generation API or to use our embedding API to compute features for a clustering algorithm." Ginkgo said it plans to roll out more models and expand API capabilities over the next year as it works towards building a robust suite of tools to help biotech and pharmaceutical companies solve complex problems. DNA Price Action: Ginkgo Bioworks shares were up 16.7% at $7.26 at the time of publication, according to Benzinga Pro. Photo: Shutterstock. Market News and Data brought to you by Benzinga APIs

Why Ginkgo Bioworks Holdings Stock Raced 9% Higher Today | The Motley Fool

The company is forging ahead with next-generation drug development solutions. Bioengineering specialist Ginkgo Bioworks Holdings (DNA 9.31%) delivered some badly needed good news for investors on Tuesday. Those folks commensurately rewarded the company by trading up its stock during that day's session, and it closed more than 9% higher in price. That was more than enough to crush the broader market that day, at least in respect to the stagnating S&P 500 index. Ginkgo's news was connected with its efforts in the artificial intelligence (AI) sphere. While that technology isn't as hot as it was for investors several months ago, there is still much interest in its power and potential. The company unveiled two new products on Tuesday linked to AI. The first is a protein large language model (LLM) it developed with its tech industry partner Alphabet's Google Cloud Consulting unit. According to the biotech, this LLM "will give individual researchers and enterprise companies the ability to develop medicines with insights from Ginkgo's private data." The company also rolled out its model application programming interface (API; a piece of software that allows different applications to work together). The API, which has been made publicly accessible on Ginkgo's website, allows researchers to work effectively with biological AI models, the company said. Ginkgo did not provide any financial details -- costs, pricing, etc. -- of either offering. Regardless, it's clear that investors are enthusiastic about its assertive push into AI and its continuing emphasis on the power of tech to aid in the development of medicines. Shareholders will be hoping that management can turn such efforts into meaningful revenue generators before long.

Ginkgo Bioworks stock retains buy rating, $3.00 target amid AI growth By Investing.com

On Tuesday, Ginkgo Bioworks Holdings Inc (NYSE:DNA) maintained its Buy rating and $3.00 price target from TD Cowen, highlighting the expansion of its partnership with Google (NASDAQ:GOOGL) Cloud. The collaboration enhances Ginkgo Bioworks' artificial intelligence (AI) capabilities, particularly in the area of AI-driven drug discovery. The updated partnership includes the integration of a new protein language model (LLM) into Ginkgo's platform. This addition provides users with access to the company's proprietary database, which is designed to facilitate the exploration of protein interactions and the optimization of lead compounds in drug development. Moreover, Ginkgo Bioworks has introduced an open API, broadening the accessibility of its AI tools to a wider audience. This move is expected to encourage the use of AI in various scientific and pharmaceutical applications by providing researchers and developers with more flexible and expansive resources. TD Cowen anticipates that Ginkgo Bioworks will continue to strengthen its AI offerings through further partnerships and product launches. These strategic moves are seen as key drivers for the company's growth in the AI sector, particularly within the context of life sciences and biotechnology. The sustained Buy rating and $3.00 price target reflect confidence in Ginkgo Bioworks' trajectory as it leverages AI technology to innovate and democratize the drug discovery process. The company's efforts to expand its AI toolbox are expected to contribute to its ongoing development and market position. In light of Ginkgo Bioworks' recent collaboration with Google Cloud to enhance its AI-driven drug discovery capabilities, InvestingPro provides valuable insights into the company's financial health and stock performance. With a market capitalization of $389.97 million, Ginkgo Bioworks is navigating a challenging financial landscape, as evidenced by a significant revenue decline of 43.45% in the last twelve months as of Q2 2024. Despite a high gross profit margin of 80.22%, the company's operating income margin has been deeply negative at -379.11% for the same period. InvestingPro Tips suggest that Ginkgo Bioworks holds more cash than debt on its balance sheet, which could provide some financial stability. Additionally, the stock is currently in oversold territory according to the Relative Strength Index (RSI), potentially indicating an opportunity for investors. However, it's important to note that analysts do not expect the company to be profitable this year, and the stock has experienced a significant decline over the past month and year. For investors interested in exploring further, InvestingPro offers additional tips on Ginkgo Bioworks, available at https://www.investing.com/pro/DNA. These insights could be crucial for making informed decisions, especially considering the company's current valuation, which implies a low revenue multiple and a poor free cash flow yield.

Ginkgo Bioworks Launches Ginkgo Datapoints to Transform AI Model Training in Biology

BOSTON, Sept. 18, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, proudly announces the launch of Ginkgo Datapoints to usher in the next era of biotechnology by making the training of AI models easier and more efficient. Ginkgo Datapoints is specialized in generating large, high-quality biological datasets with a fast turnaround time and at a competitive price per datapoint with a streamlined deal structure. Ginkgo Datapoints will launch with several data generation products this Fall including protein characterization and functional genomics. The Functional Genomics product, the flagship offering under Ginkgo Datapoints, available now, delivers large-scale perturbation datasets that power our partners' AI models of cell and disease biology for use in target identification and validation and drug discovery. Ginkgo Datapoints addresses some of the most significant challenges in the industry for AI model training: data availability, quality, and uniformity. Jason Kelly, CEO of Ginkgo Bioworks: "The launch of Ginkgo Datapoints marks a significant step forward in our mission to make biology easier to engineer. With Ginkgo Datapoints, we're passing on our economies of scale to our customers by generating large, high-quality datasets for our customers at a price per dataset that makes training biological foundation models feasible. Ginkgo Datapoints is more than just a service -- it's a commitment to driving innovation and accelerating the development of new therapies and solutions across the biotech industry." John Androsavich, General Manager of Ginkgo Datapoints: "There's a burgeoning market of drug and product developers who want to take advantage of AI, and their models are ravenous for data. With Ginkgo Datapoints, we're answering the call for how to generate the data this new era of life sciences needs. We're focusing Ginkgo's massive infrastructure to do biological data generation at AI scale, allowing our Datapoints customers to make bold bets in model training that will meaningfully impact drug discovery for target ID or fields like antibody therapeutics. Our goal is to eliminate the data bottlenecks slowing down AI-driven advancements in biology, and I'm excited about the team and technologies we've assembled for it." Ginkgo Datapoints products are the next evolution of Ginkgo's previously launched Lab Data-as-a-Service offerings. These products will offer key features that are of critical importance to customers building AI for biology, ranging from biopharmas to techbio to big tech companies. Ginkgo Datapoints' Functional Genomics product is designed for: Ginkgo Datapoints embodies Ginkgo's mission of making biology easier to engineer by unlocking the full potential of AI in biology. By generating the data that the industry needs, Ginkgo Datapoints is poised to be a vital resource for researchers and companies leveraging AI and machine learning for drug discovery and beyond. Unlock AI. Unlock Biology. Learn more about Ginkgo Datapoints and how we can accelerate your AI efforts with our cutting-edge data services here. About Ginkgo Bioworks Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn. This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of Ginkgo Datapoints and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) the outcome of any pending or potential legal proceedings against Ginkgo, (vii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (viii) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (ix) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 29, 2024, Ginkgo's most recent quarterly report on Form 10-Q, and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

Google Cloud Expands Its Partnership With Ginkgo Bioworks For Two New AI-Tools Faster Drug Development - Alphabet (NASDAQ:GOOGL), Ginkgo Bioworks Holdings (NYSE:DNA)

Ginkgo's API offers competitive pricing and a free tier, making advanced AI tools accessible to researchers and scientists worldwide. Tuesday, Ginkgo Bioworks Holdings, Inc. DNA announced two tools to streamline the drug development process for pharmaceutical and biotech companies. Building on its partnership with Alphabet Inc's GOOG GOOGL Google Cloud, Ginkgo introduced a protein large language model (LLM) and a model API, both designed to accelerate medicine development by leveraging AI and proprietary biological data. These offerings aim to simplify and enhance how researchers and companies discover new therapeutics. Researchers at Google DeepMind have developed AlphaFold 3, an new artificial intelligence (AI) model. AlphaFold 3 can predict the structure and interactions of biological molecules. This includes proteins, DNA RNA, and small molecules that could function as drugs. The new protein LLM, developed in collaboration with Google Cloud Consulting and built on Vertex AI, offers powerful insights derived from Ginkgo's private data to individual researchers and enterprise companies. The model can help identify new therapeutic targets by analyzing protein structures and interactions, speeding up the discovery and development of life-saving medicines. This tool is expected to revolutionize drug development pipelines, optimizing the process from lead identification to final approval. In addition to the LLM, Ginkgo has launched its model API, an accessible and affordable tool aimed at providing machine learning scientists with AI models trained on Ginkgo's proprietary protein and DNA datasets. This API is available on Ginkgo's website, with plans for enterprise access through Google Cloud's Vertex AI Model Garden. The API enables users to generate insights through advanced methods like masked language modeling and embedding calculations. Ankit Gupta highlighted that predictions on protein sequences could be obtained for as little as $0.18 per million tokens, allowing researchers to scale their experiments without incurring high costs. Ginkgo plans to release more models over the next year, broadening the API's capabilities and expanding its suite of tools to tackle complex drug discovery, synthetic biology, and genomics challenges. Price Action: DNA stock is up 11.60% at $6.95 at the last check on Tuesday. Read Next: Amazon's Leaner Structure and AI Chip Partnership with Intel Could Boost Growth: BofA Analyst. Photo via Shutterstock Market News and Data brought to you by Benzinga APIs